drugset / Trial / NCT05985850
Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy
Phase 2
Recruiting
24 enrolled
BC Centre on Substance Use
Canadian Institutes of Health Research (CIHR) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This pilot study will evaluate the feasibility and safety of using 1:1 tetrahydrocannabinol (THC):Cannabidiol (CBD) cannabis oil as an adjunct therapy to methadone-based Opioid Agonist Therapy (OAT) for individuals with opioid use disorder (OUD) in a community setting.
Timeline
- Start
- 2024-05-23
- Primary completion
- 2026-03
- Completion
- 2027-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Aurora 1:1 Drops (Indica) | Unknown | 5 mg | Other |